FoRx Therapeutics discloses its Board with Dr Colin Goddard as Executive Chairman and announces €10m seed financing led by M Ventures, Novartis Venture Fund and Omega Funds

– SWITZERLAND, Basel –  FoRx Therapeutics AG, the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways, today announced the closing of a EUR 10 million seed financing led by M Ventures, Novartis Venture Fund and Omega Funds.

Nuvation Bio strengthens its Board alongside raising $275m Series A financing led by Omega Funds

– USA, NY –  Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, today announced the closing of $275 million in an oversubscribed Series A funding round led, structured and syndicated by Omega Funds and including participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI, ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital and other institutional investors.…